Sanofi-Aventis (SNY) completes its improved $20.1B offer for Genzyme (GENZ) after 84.6% of the...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi-Aventis (SNY) completes its improved $20.1B offer for Genzyme (GENZ) after 84.6% of the U.S. company's stock was tendered. Sanofi-Aventis will now start merging the U.S. biotech's operations into its business and add products for rare diseases to its growth areas. (previously)